Results 81 to 90 of about 2,207,306 (351)

Performance of a building integrated collector for solar heating and radiant cooling [PDF]

open access: yes, 2011
Due to their limited temperature range, unglazed solar collectors have long been relegated to providing low cost heating in applications such as swimming pool heating systems.
Anderson, Timothy Nicholas   +2 more
core   +1 more source

Cold r-Process in Neutrino-Driven Winds

open access: yes, 2007
The r-process in a low temperature environment is explored, in which the neutron emission by photodisintegration does not play a role (cold r-process). A semi-analytic neutrino-driven wind model is utilized for this purpose.
Goriely S., Shinya Wanajo, Takahashi K.
core   +1 more source

Nonlinear interaction between three inertial Alfv\'{e}n waves [PDF]

open access: yes, 2006
The resonant coupling between Alfv\'{e}n waves is reconsidered. New results are found for cold plasmas there temperature effects are negligible.Comment: To appear in J.
Brodin, G., Shukla, P. K., Stenflo, L.
core   +2 more sources

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

open access: yesMolecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son   +13 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

A Tale of Three Galaxies: Deciphering the Infrared Emission of the Spectroscopically Anomalous Galaxies IRAS F10398+1455, IRAS F21013-0739 and SDSS J0808+3948

open access: yes, 2015
The \textit{Spitzer}/Infrared Spectrograph spectra of three spectroscopically anomalous galaxies (IRAS~F10398+1455, IRAS~F21013-0739 and SDSS~J0808+3948) are modeled in terms of a mixture of warm and cold silicate dust, and warm and cold carbon dust ...
Hao, Lei   +3 more
core   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Oil Hydrocarbon Degradation by Caspian Sea Microbial Communities

open access: yesFrontiers in Microbiology, 2019
The Caspian Sea, which is the largest landlocked body of water on the planet, receives substantial annual hydrocarbon input from anthropogenic sources (e.g., industry, agriculture, oil exploration, and extraction) and natural sources (e.g., mud volcanoes
John I. Miller   +14 more
doaj   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy